



20th Annual Meeting of the Swiss Transplantation Society



January 26-27, 2023

Congress Hotel Seepark
Thun, Switzerland

Congress Organization

Prof. Hendrik Tevaearai, President STS
PD Dr Patrizia Amico,
Chair of the Scientific Committee

Congress Secretariat


Meeting-com Sàrl Congress Organisation
www.meeting-com.ch • info@meeting-com.ch

Online registration on [www.meeting-com.ch/
Conferences & Meetings/2023](http://www.meeting-com.ch/Conferences%20&%20Meetings/2023)

PROGRAM



Your partner in transplantation



**Every life line
tells a story**

Welcome letter

Dear Colleagues, dear Friends,

It is with great pleasure that I invite you, on behalf of the Swiss Transplantation Society, to join us at the 20th Annual Congress on January 26 and 27, 2023 at the Congress Hotel Seepark, in Thun.

For this annual meeting, our scientific committee, chaired by Patrizia Amico and assisted by Aurelia Schnyder, has prepared a very attractive program, covering very timely topics and relevant issues, both for transplant patients and for transplant specialists.

On Thursday, after the traditional and always very informative reports of Swiss Transplant and the STCS, our program will start with a keynote lecture on equity in accessibility to transplantation. This will be followed by an update on the strategies regarding CMV issues in solid organ and hematopoietic stem cell transplantation. You don't want then to miss our also now traditional coordinators' corner, and very important, please come to cheer our young colleagues who will present, during the STS award competition session, the 6 best papers published in 2022 as selected by our scientific committee. The prizes will be awarded the same evening during our networking dinner.

The Friday programs will start with an interesting patient's perspective on organ living donation. Immunosuppression in young versus elder recipients, management of cancer after transplantation, and the role of the microbiome in transplantation will then be the topics presented during the day.

Our program will end up with the ceremony of the STS Excellence and Innovation awards 2022, and a final session on the challenges the various organ specialists are currently facing in transplantation.

I would like now to thank our sponsors for their very essential participation and of course our colleagues at meeting.com for their faithful, efficient and friendly support.

The Board of our Society, the Scientific Committee and myself are very much looking forward to seeing you soon in Thun and wish you all a very pleasant and fruitful congress.

Prof. Hendrik Tevaeearai Stahel
President of the STS

Credits

The credits are in demand to the following societies

SGC/SSC Schweizerische Gesellschaft für Chirurgie Société Suisse de Chirurgie	8 credits
SGI/SSI Schweizerische Gesellschaft für Infektiologie Société Suisse d'Infectiologie	in demand
SGG/SSG Schweizerische Gesellschaft für Gastroenterologie Société Suisse de Gastroentérologie	10 credits
SSAI/SGAI Schweizerische Gesellschaft für Allergologie und Immunologie Société Suisse d'Allergologie et d'Immunologie	10 credits
SGN/SSN Schweizerische Gesellschaft für Nephrologie Société Suisse de Néphrologie	12 credits
SGHC/SSCC Schweizerische Gesellschaft für Herz- und thorakale Gefässchirurgie Société Suisse de Chirurgie Cardiaque et Vasculaire Thoracique	2 credits
SSAPM Schweizerische Gesellschaft für Anästhesiologie und Perioperative Medizin Société Suisse d'Anesthésiologie et de Médecine Périopératoire	11 credits
SGAIM/SSMIG Schweizerische Gesellschaft für Allgemeine Innere Medizin Société Suisse de Médecine Interne Générale	5 credits
SGH/SSH Schweizerische Gesellschaft für Hämatologie Société Suisse d'Hématologie	12 credits
SSP Schweizerische Gesellschaft für Pneumologie Société Suisse de Pneumologie	11 credits
SGI/SSMI Schweizerische Gesellschaft für Intensivmedizin Société Suisse de Médecine Intensive	11 credits

General information

Venue

Congress Hotel Seepark
Seestrasse 47, 3602 Thun - www.seepark.ch
T +41 (0)33 226 12 12 - info@seepark.ch

Congress Office

Office Secretariat STS - meeting-com Congress Organisation
Rue des Pâquis 1 - CP 100 - 1033 Cheseaux-sur-Lausanne
T +41 (0)21 312 92 61 - info@meeting-com.ch



Registration fees

	Early bird Until Dec. 18, 2022	Late As from Dec. 19, 2022 and onsite
Medical doctors/participants STS MEMBER	CHF 230.00	CHF 270.00
Medical doctors/JUNIOR < 35 years STS MEMBER	CHF 190.00	CHF 230.00
Medical doctors/JUNIOR < 35 years STS NON-MEMBER	CHF 220.00	CHF 250.00
Medical doctors/participants STS NON-MEMBER	CHF 360.00	CHF 390.00
Transplant care specialists & TPL coordinators STS MEMBER	CHF 160.00	CHF 200.00
Transplant care specialists & TPL coordinators STS NON-MEMBER	CHF 240.00	CHF 260.00

Networking dinner - Thursday January 26, 2023

Participation costs 1 person	CHF 120.00 (TTC)
2 persons	CHF 240.00 (TTC)

Including

Attendance at the scientific sessions and exhibition area, certificate of participation, coffee breaks and lunches according to the program. The networking dinner is not included and has to be booked separately.

Thursday, January 26, 2023

09.30 - 12.00

Swiss Transplant Working Group Meetings (to be registered separately)

13.00 - 13.05

Welcome

Hendrik Tevaeearai, Bern - President of the Swiss Transplantation Society

Room Genève

13.05 - 13.25

Swiss Transplant Annual Activity Report

Franz Immer, Franziska Beyeler, Swiss Transplant, Bern

13.25 - 13.45

STCS Report

Jürg Steiger, Michael Koller; Basel

13.45 - 14.15

KEYNOTE LECTURE

Room Genève

Chair

Vanessa Banz Wüthrich, Bern

Equity in Accessibility to Transplantation

Samia Hurst-Majno, Geneva

14.15 - 15.30

SPONSORED SYMPOSIUM by TAKEDA

Room Genève

Session 1

Chair

CMV in SOT and HSCT

Nicolas Müller, Zurich



14.15 - 14.40

**Update of CMV in SOT:
Preventive strategies and new biomarkers**

Oriol Manuel, Lausanne

14.40 - 15.05

**Update on CMV in HSCT: Resistant/refractory infection,
drugs and personalized medicine**

Nina Khanna, Basel

15.05 - 15.30

Discussion

15.30 - 16.00

Coffee break - visit of the exhibition

Foyer 1st floor

Thursday, January 26, 2023

16.00 - 17.30

Session 2

Chairs

COORDINATOR'S CORNER (program with SDTA) Room Genève

Franz Immer, Bern; Philippe Compagnon, Geneva

16.00 - 16.30

Update on Donor Lung Preservation

György Lang, Zurich

16.30 - 17.00

DCD Heart Transplantation. Challenges and Opportunity

Simon Messer, UK

17.00 - 17.30

Machine liver perfusion

Philipp Dutkowski, Zurich

Thursday, January 26, 2023

17.30 - 18.30

Session 3

Chair

STS AWARDS

Déla Golshayan, Lausanne

Oral presentation
of the six highest ranking papers

17.30 - 17.40

Frailty predicts outcomes in cystic fibrosis patients listed for lung transplantation

Angela Koutsokera, Lausanne

17.40 - 17.50

Successful induction of specific immunological tolerance by combined kidney and hematopoietic stem cell transplantation in HLA-Identical Siblings

Kerstin Hübel, Zurich

17.50 - 18.00

Impact of different urinary tract infection phenotypes within the first year post-transplant on renal allograft outcomes

Jakob Brune, Basel

18.00 - 18.10

Long-term outcomes of transplant kidneys donated after circulatory death

Amélie Müller, Zurich

18.10 - 18.20

Transplantation of a human liver following 3 days of ex situ normothermic preservation

Pierre-Alain Clavien, Zurich

18.20 - 18.30

Subnormothermic Ex Vivo Porcine Kidney Perfusion Improves Energy Metabolism: Analysis Using 31P Magnetic Resonance Spectroscopic Imaging

Thomas Agius, Lausanne

Room Genève



18.30 - 19.00

General Assembly

Room Genève

19.20

Networking Dinner & STS Awards

Parksaal Hotel Seepark



EVUSHELD®
tixagevimab, cilgavimab

SCHÜTZEN SIE IHRE
IMMUNGESCHWÄCHTEN
PATIENT:INNEN
VOR COVID-19.¹



Besuchen Sie
www.evusheld.ch
oder scannen Sie
den QR-Code um
mehr zu erfahren.

**EVUSHELD® ist indiziert für die
Prä-Expositions-Prophylaxe
einer COVID-19-Erkrankung bei
Erwachsenen und Jugendlichen
ab 12 Jahren mit mindestens
40 kg Körpergewicht.¹**

1. Fachinformation EVUSHELD®, Stand: September 2022, www.swissmedicinfo.ch. Fachpersonen können die genannten Referenzen bei AstraZeneca AG anfordern.

EVUSHELD®. Z: Tixagevimabum, Cilgavimabum (hergestellt in Ovarialzellen des chinesischen Hamsters (CHO) durch rekombinante DNA-Technologie). Abgabekategorie [A]. **I:** EVUSHELD® (Tixagevimab und Cilgavimab) wird angewendet zur Prä-Expositionsprophylaxe von COVID-19 bei Erwachsenen und Jugendlichen (ab 12 Jahren und mit einem Körpergewicht von mindestens 40kg, die nicht fähig sind eine angemessene Immunantwort auf die SARS-CoV2-Impfung zu erzeugen und derzeit nicht mit SARS-CoV-2 infiziert sind und die in letzter Zeit keinen Kontakt zu einer mit SARS-CoV-2 infizierten Person hatten. Nicht zur Behandlung oder Post-Expositionsprophylaxe zugelassen oder als Ersatz für eine Impfung vorgesehen. Anwendung gemäss den offiziellen Empfehlungen*. **D:** Injektionslösung zur intramuskulären (i.m.) Anwendung durch eine medizinische Fachperson. Zwei Durchstechflaschen (150mg Tixagevimab (100mg/ml) und 150mg Cilgavimab (100mg/ml)). Die empfohlene Dosierung beträgt 300mg* i.m. EVUSHELD® angewendet als zwei separate, aufeinanderfolgende intramuskuläre Injektionen. **KI:** Überempfindlichkeit gegen die Wirkstoffe oder einen der unter Hilfsstoffe genannten sonstigen Bestandteile. **V:** Anzeichen und Symptome einer klinisch signifikanten Überempfindlichkeitsreaktion oder Anaphylaxie; klinisch signifikante Blutgerinnungsstörungen; Patienten sollten auf Anzeichen oder Symptome hingewiesen werden, die auf ein kardiovaskuläres Ereignis hindeuten; Antivirale Resistenz. **IA:** Es wurden keine Studien zur Erfassung von Wechselwirkungen durchgeführt. **UAW:** Häufig: Überempfindlichkeit, Reaktion an der Injektionsstelle. Gelegentlich: Injektionsbedingte Reaktion. Stand der Information: September 2022.

* 600 mg i.m. gemäss SSI-Kriterienliste.

Weitere Informationen: www.swissmedicinfo.ch oder AstraZeneca AG, Neuhofstrasse 34, 6340 Baar. www.astrazeneca.ch

▼ Dieses Arzneimittel unterliegt einer zusätzlichen Überwachung. Für weitere Informationen, siehe Fachinformation von EVUSHELD® auf www.swissmedicinfo.ch.

CH-6980-PHC-11/2022

Friday, January 27, 2023

08.30 - 09.00

PRESENTATION OF THE SELECTED HONORARY MEMBER

09.00 - 10.15

Session 4

**SWISS ORGAN LIVING -
DONOR HEALTH REGISTRY (SOL-DHR)**

Room Genève

Chair Patrizia Amico, Basel

09.00 - 09.25 **30 years of Swiss Organ Living - Donor Health Registry - It's time for a look back and to move on**
Patricia Hirt-Minkowski, Basel

09.25 - 09.45 **The patient's view**

09.45 - 10.15 **30mn-discussion**

10.15 - 10.45

Coffee break - visit of the exhibition

Foyer 1st floor

10.45 - 11.40

**SPONSORED SYMPOSIUM BY ASTELLAS
PROBLEMS AND CHALLENGES
IN MANAGING PATIENTS
WITH IMMUNOSUPPRESSION**

Room Genève

Chair Aurelia Schnyder, St.Gallen

10.45 - 10.50 **Introduction**

10.50 - 11.10 **The young recipient**
Barbara Wildhaber, Valérie McLin; Geneva

11.10 - 11.30 **The adult recipient**
Caroline Wehmeier, Basel

11.30 - 11.40 **Discussion**



11.40 - 12.30

Session 5

**MANAGEMENT OF CANCER
IN TRANSPLANTATION**

Room Genève

Chair Patrizia Amico, Basel

11.40 - 12.00 **Skin cancer after transplantation**
Mirjam Nägeli, Zurich

12.00 - 12.20 **Solid tumor after transplantation**
Valérie Cristina, Lausanne

12.20 - 12.30 **Discussion**

Friday, January 27, 2023

12.30 - 13.30

Lunch break - visit of the exhibition

Foyer 1st floor

13.30 - 14.15

Session 6

MICROBIOME IN TRANSPLANTATION

Room Genève

Chair Hendrik Tevaeearai, Bern

13.30 - 14.00 **The importance and role of the microbiome in solid organ transplantation**
Andrew Macpherson, Bern

14.00 - 14.15 **Discussion**

14.15 - 14.45

STS EXCELLENCE & INNOVATION AWARDS 2022

Room Genève

Chair with the kind support of Astellas
Markus Barten, President of the STS Excellence & Innovation Awards, Hamburg

14.45 - 16.15

Session 7

CHALLENGES ACROSS DIFFERENT ORGANS

Room Genève

Chair Vanessa Banz Wüthrich, Bern

14.45 - 15.00 **Hematopoietic cell transplantation**
Jakob Passweg

15.00 - 15.15 **Lung transplantation for Covid-19 ARDS**
György Lang, Zurich

15.15 - 15.30 **Heart transplantation**
Matthias Siepe, Bern

15.30 - 15.45 **Pancreas / Islet transplantation**
Andrea Peloso, Geneva

15.45 - 16.00 **Liver transplantation**
Philippe Compagnon, Geneva

16.00 - 16.15 **Kidney transplantation**
Isabelle Binet, St.Gallen

16.15

Closing remarks

Hendrik Tevaeearai, Bern
President of the Swiss Transplantation Society

Room Genève

Committees

STS Board

Prof. Hendrik Tevaearai, Bern	President
Prof. Philipp Dutkowski, Zurich	President-elect
Dr Aurelia Schnyder, St.Gallen	Secretary
Prof. Jean Villard, Geneva	Treasurer
PD Dr Patrizia Amico, Basel	Science and Research
Dr Angela Koutsokera, Lausanne	Member
Dr Federico Storni, Bern	Member
Dr Isabelle Binet, St.Gallen	Past President

STS Scientific Committee Members

Name	Institution	Transplantation Field
Amico Patrizia	Basel	Immunology & Kidney
Banz Wüthrich Vanessa	Bern	Liver
Duchosal Michel	Lausanne	Bone marrow
Dutkowski Philipp	Zurich	Liver
Ferrari-Lacraz Sylvie	Geneva	Immunology
Folie Patrick	St.Gallen	Kidney
Golshayan Déla	Lausanne	Kidney
Hirt-Minkowski Patricia	Basel	Kidney
Inci Ilhan	Zurich	Lung
Müllhaupt Beat	Zurich	Liver
Müller Nicolas	Zurich	Infectious diseases
Neofytos Dionysios	Geneva	Infectious diseases
Tevaearai Hendrik	Bern	Heart

Kidney Assist Transport

Unlock the power of oxygen



Visit our booth to learn more about oxygenated machine perfusion

CURRENT POST-TRANSPLANT CMV TREATMENT

IS A BALANCING ACT BETWEEN SAFETY AND EFFICACY¹

and can lead to resistance², graft rejection³, neutropenia² and nephrotoxicity⁴



If you have any questions, contact us at info@takeda.ch

CMV = Cytomegalovirus

REFERENCES: 1. Khurana MP, et al. Risk Factors for Failure of Primary (Val)ganciclovir Prophylaxis Against Cytomegalovirus Infection and Disease in Solid Organ Transplant Recipients. *Open Forum Infect Dis.* 2019;6.doi:10.1093/ofid/ofz215.; 2. Kotton CN, et al. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. *Transplantation.* 2018;102:900-931.; 3. Felipe CR, et al. The current burden of cytomegalovirus infection in kidney transplant recipients receiving no pharmacological prophylaxis. *J Bras Nephrol.* 2017;70:515-523.; 4. Razonable RR, et al. Cytomegalovirus in solid organ transplantation. *Am J Transplant.* 2013;13(suppl 4):93-106.

Healthcare professionals may request a complete copy of the cited literature from the pharmaceutical company.

C-ANPROM/CH/MARI/0017-08/2022



Takeda Pharma AG,
Thurgauerstrasse 130,
8152 Glattpark (Opfikon),
www.takeda.ch

Sponsors

PLATINUM



GOLD



Sponsors





21st Annual Meeting of the Swiss Transplantation Society



January 25-26, 2024

Congress Hotel Seepark
Thun, Switzerland

Congress Secretariat

Meeting-com Sàrl Congress Organisation
www.meeting-com.ch • info@meeting-com.ch

SAVE THE DATE